Drug profile · INN
eptinezumab-jjmr
VYEPTI
eptinezumab-jjmr (VYEPTI) is a calcitonin gene-related peptide inhibitor. Route of administration: injection. Current US regulatory status: approved.
Drug details — eptinezumab-jjmr
- US status
- approved
- Class
- —
- Route
- INJECTION
- Patents
- 0
- Programs
- 4
- Data quality
- 0.84
Quick answer
eptinezumab-jjmr (VYEPTI) is a calcitonin gene-related peptide inhibitor. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
Calcitonin gene-related peptide inhibitor
Primary target: Calcitonin gene-related peptide
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Recent coverage
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is eptinezumab-jjmr?
eptinezumab-jjmr (VYEPTI) is a calcitonin gene-related peptide inhibitor. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for eptinezumab-jjmr?
VYEPTI is a marketed brand name for eptinezumab-jjmr. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of eptinezumab-jjmr?
eptinezumab-jjmr has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.